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Abstract
In prostate cancers (PCa), the formation of malignant
stroma may substantially influence tumor phenotype
and aggressiveness. Thus, the impact of the orthotopic
and subcutaneous implantations of hormone-sensitive
(H), hormone-insensitive (HI), and anaplastic (AT1)
Dunning PCa in rats on growth, microcirculation, and
metabolism was investigated. For this purpose, dy-
namic contrast-enhancedmagnetic resonance imaging
and 1H magnetic resonance spectroscopy ([1H]MRS)
were applied in combination with histology. Consistent
observations revealed that orthotopic H tumors grew
significantly slower compared to subcutaneous ones,
whereas the growth of HI and AT1 tumors was com-
parable at both locations. Histologic analysis indicated
that glandular differentiation and a close interaction of
tumor cells and smooth muscle cells (SMC) were
associated with slow tumor growth. Furthermore,
there was a significantly lower SMC density in sub-
cutaneous H tumors than in orthotopic H tumors. Per-
fusion was observed to be significantly lower in
orthotopic H tumors than in subcutaneous H tumors.
Regional blood volume and permeability–surface area
product showed no significant differences between
tumor models and their implantation sites. Differences
in growth between subcutaneous and orthotopic H
tumors can be attributed to tumor–stroma interac-
tion and perfusion. Here, SMC, may stabilize glandular
structures and contribute to the maintenance of differ-
entiated phenotype.
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Introduction
Autopsy studies indicate that almost 30% of all men older
than 50 years show microscopic prostate cancers (PCa)
[1,2]. However, in contrast to most other malignant tumors,
there is a high discrepancy between prevalence and mortality,
and < 10% of men with PCa suffer from symptomatic disease
during their lifetime [3]. About 29% of white men and 44% of
black men are estimated to be overdiagnosed and overtreated
[4]. Thus, there is an essential demand to distinguish aggres-
sive PCa requiring therapeutic intervention from low malignant
tumors, which will not become symptomatic.
Germline mutations leading to the dedifferentiation of
normal prostate epithelium into androgen-independent PCa
have been identified. The final step from localized PCa to
metastatic phenotype is accompanied by androgen receptor
changes and specific gene amplifications and losses [5]. Com-
pared with their primary tumors, metastases are frequently
marked by a faster and more infiltrative growth [6]. Besides
genetic changes, the degree to which the heterotopic localiza-
tion of metastases additionally influences phenotypic changes
between primary tumors and metastases is poorly understood.
This may be related to further selection of more resistant
and aggressive subclones, the interaction of tumor cells with
the surrounding fibroblastic stroma, and the development
of neovascularization [7,8].
Experiments performed by Cunha et al. [7] and Hayward et al.
[9] demonstrated that there is an epithelial–mesenchymal inter-
action in PCa development and that normal epithelial cells
can be transformed by their microenvironment. Thus, aberrant
interactions are most likely relevant in PCa development, and
their investigation in experimental PCa may provide promising
options for diagnosis and therapy.
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Noninvasive imaging techniques have gained importance
in the investigation of tumor growth and spread. Noninvasive
optical imaging of stable transfected cell lines expressing
fluorescent molecules is of high value in preclinical research
[10,11]. Magnetic resonance imaging (MRI) is frequently
used for the detection and staging of PCa in patients. Recent
developments in MRI and magnetic resonance spectros-
copy (MRS) have improved our understanding of tumor
biology and have particularly enabled the detection and char-
acterization of PCa and lymph node metastasis [12–14]. In
this context, improved sensitivity and specificity for the de-
tection of PCa were achieved by supplementing morphologic
MRI with [1H]NMR spectroscopic imaging [15,16] to as-
sess tumor metabolism. Furthermore, dynamic contrast-
enhanced MRI (DCE-MRI) is frequently used to characterize
microcirculation in PCa [17,18]. It has been shown that even
simple parameters describing signal time courses after in-
jection of a contrast agent, such as the initial slope and the
maximum of relative signal enhancement, assist in the differ-
entiation between PCa and normal peripheral glands [18].
However, for a more precise analysis of tumor physiology,
pharmacokinetic models providing quantitative data on re-
gional blood volume (RBV), regional blood flow (RBF; perfu-
sion), and capillary permeability are highly desirable. These
parameters can be estimated, for example, by pharmaco-
kinetic analysis of acquired DCE-MRI data using an open
two-compartment model [19].
Clinical [1H]MRS studies have demonstrated that signal
intensities of the metabolites citrate (Ci; multiplet centered at
chemical shift d = 2.6 ppm), choline and choline-containing
compounds (Cho; d = 3.22 ppm), and creatine and phospho-
creatine (Cr; d = 3.03 ppm) provide a measure for the bio-
chemical characterization of prostatic lesions (‘‘CC/C value’’).
In the normal prostate, Ci is secreted and stored in the
peripheral zone and, therefore, causes an intense signal in
the [1H]MRspectrum. In PCa, theCi concentration, hence the
corresponding [1H]MR signal, often exhibits a decrease. An
elevated Cho signal indicates increased membrane turnover
and cell necrosis. Cr are related to the energy metabolism
of cells and are useful for standardization because these
metabolites usually do not increase in tumors. Thus, an in-
creased amount of Cho typically found in tumors with high
proliferative activity [20,21] and a decrease in Ci + Cr signal
intensities have proven to be useful markers of PCa [15].
Lipid fractions, which are an indicator of cell degeneration
(i.e., of necrosis and, therefore, possibly of anaplasia), have
not been studied in PCa so far. However, a recent study on
hepatocellular carcinomas indicated that dedifferentiation
of liver lesions goes with an increase in the concentrations
of free lipids [22]. Thus, lipid fractions are also a possible
candidate for supplementing the grading of PCa.
However, up to now, it is uncertain whether DCE-MRI and
[1H]MRS are capable of assessing tumor aggressiveness
[23–25]. In this context, the correct staging of PCa has been
revealed to be complicated by the heterogeneous and multi-
focal nature of this tumor. Usually, there is no solitary PCa
clone deriving from one tumor cell but a conglomerate of
benign glandular structures, preneoplastic foci (prostatic
intraepithelial neoplasia), and neoplastic foci with different
grades of dedifferentiation [26]. These aspects of PCa have
been considered in histologic Gleason grading, which proved
to be an excellent prognostic indicator [27].
Based on these findings, we investigated the influence of
tumor environment on the development of experimental
prostate tumors with different malignancies in rats. Tumors
were exposed to different microenvironments by orthotopic
and subcutaneous implantations. Tumor growth, spread,
microcirculation, andmetabolismwere evaluated bymorpho-
logic MRI, DCE-MRI, and [1H]MRS, in combination with
histopathological analysis.
Materials and Methods
Animals and Tumor Models
Experiments were performed with the approval of the
institutional committee for animal research and in confor-
mity with national guidelines for the care and use of labora-
tory animals.
As a tumor model for PCa, the original Dunning R3347
PCa of rats from J. T. Isaacs (John Hopkins, Baltimore, MD)
was chosen, which spontaneously arose in a Copenhagen
rat and was isolated from lymph node metastasis in 1963
[28]. Different sublines were drawn by repeated passaging in
castrated rats. Their common characteristic is resemblance
to human prostate carcinoma with respect to both histologic
and enzymatic patterns [29,30].
In the present study, the well-characterized sublines
H (hormone-sensitive), HI (hormone-insensitive), and AT1
were chosen for their different volume-doubling times, hor-
monal dependency, and histologic phenotype. The subtype H
was observed to be highly differentiated and hormone-
dependent, whereas the HI Dunning tumor was moderately
differentiated, was insensitive to hormones, and produced
mucin. The AT1 subline used as the third model forms ana-
plastic hormone-independent tumors without glandular diff-
erentiation. The volume-doubling time ranged from 20 days
for subtype H, to 10 days for subtype HI, to 2.7 days for AT1
tumors. The three sublines exhibited a low metastatic poten-
tial in common [31].
A total of n = 49 adult male Copenhagen rats (body weight:
f 180–200 g; age: 4–6 weeks) were included. Tumors of
the three sublines were inoculated subcutaneously in the
right hind leg using fragments of donor tumors with a volume
of approximately 1 to 2 mm3. Alternatively, tumor fragments
were implanted orthotopically in the dorsolateral lobe of
the prostate following a protocol described by Lein et al.
[32,33] and Hahn et al. [34]. In our study, a higher number
of orthotopic H tumor implantations were necessary due to a
lower tumor take rate (Figure 1).
Anesthesia
For tumor inoculation and MR examinations, the rats were
anesthetized by inhalation of a mixture of isoflurane (1.5%),
N2O (35%), and oxygen (60%). Tail vein was catheterized
with a 26-gauge cannula (Abbott, Sligo, Ireland).
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MRI
MRI was performed on a clinical 1.5-T whole-body MR
system (Magnetom Symphony; Siemens Medical Solutions,
Erlangen, Germany) using a home-built coil for radio-
frequency excitation and detection, designed as a cylindrical
volume resonator with an inner diameter of 83 mm and a
usable length of 120 mm [17].
Animals with orthotopic tumors were examined with
transversal and sagittal imagings, whereas those with sub-
cutaneous tumors were examined with transversal and cor-
onal T2-weighted (T2w) turbo spin echo (TSE) MR sequences
according to the following protocols: transversal T2w TSE: re-
petition time TR = 3240 milliseconds, echo time TE = 81 milli-
seconds, matrix size MA = 256  152, field of view (FOV) =
90 54 mm2, slice thickness TH = 1.5 mm; coronal T2w TSE:
TR = 3240 milliseconds, TE = 72 milliseconds, MA = 256 
108, FOV = 150 63mm2, TH = 2mm; sagittal T2w TSE: TR =
3240 milliseconds, TE = 78 milliseconds, MA = 255  88,
FOV = 150  51 mm2, TH = 1 mm.
When tumors reached a diameter of approximately 5 mm,
morphologic MRI was supplemented with DCE-MRI. On
the basis of acquired T2w images, two transversal sections
were defined (TH = 4.5 mm, FOV = 130 98 mm2): one at the
position of maximum tumor size, and the other at the heart
level to determine the arterial input function from the left
ventricle or the thoracic aorta. To estimate the precontrast
longitudinal relaxation times (T1) of blood and carcinoma,
T1-weighted (T1w) images were acquired from predefined sec-
tions using a saturation–recovery Turbo FLASH sequence
(TR = 373 milliseconds, TE = 1.76 milliseconds, flip angle a =
20j, MA = 192  144, FOV = 130  98 mm2) with recovery
times (TREC) varying between 200 and 4000 milliseconds.
The same sequence was used for DCE-MRI, with TR =
373 milliseconds, TE = 1.76 milliseconds, TREC = 130 milli-
seconds, a = 20j, and TH = 4.5 mm. In total, 512 dynamic
scans were acquired from both sections, with a temporal
resolution of 0.6 s. Five seconds after starting DCE-MRImea-
surements, 200 ml (0.1 mmol/kg body weight) of the para-
magnetic contrast agent Gd-DTPA-BMA (Omniscan; GE
Healthcare, Munich, Germany) was injected manually within
2 seconds into the tail vein of rats. Finally, postcontrast
high-resolution T1w FLASH images covering the whole
tumor region were obtained (TR = 600 milliseconds, TE =
14 milliseconds, MA = 144  256, FOV = 72  54 mm2,
a = 90j, TH = 1.5 mm).
MRS
When subcutaneous tumors exhibited diameters larger
than 5 mm, localized [1H]MR spectra were obtained using
an horizontal-bore (20 cm) animal spectrometer with B0 =
9.4 T (9.4/20 BioSpec; Bruker BioSpin MRI GmbH, Ettlingen,
Germany). Following T2w MRI for tumor localization, single-
voxel [1H]MRS was performed [point-resolved spectroscopy
(PRESS) with selective water signal suppression, TR =
2000 milliseconds, TE = 14 milliseconds, number of excita-
tions = 128, voxel size = 4  4  4 mm3] using a surface coil
of 2 cm diameter. Three subcutaneous tumors of each sub-
line were examined, and each tumor was measured thrice
with the same sequence parameters for validation of intra-
individual reproducibility. Attempts to acquire MR spectra
from the prostate failed because of varying susceptibilities
in the pelvis and markedly lower sensitivity of the surface
coil to intraprostatic signals compared to subcutaneously im-
planted tumors.
Data Analysis
Tumor volumes were estimated by assuming ellipsoidal
shapes from tumor diameters determined for three ortho-
gonal directions from T2w MR images. Due to the presence of
large variations in growth rates between different sublines,
Figure 1. Study plan. The study plan includes the number of animals in which H, HI, and AT1 tumors were implanted and the number of implantations that led to
successful tumor growth (take rate in brackets). Bottom line: Time intervals of examinations with MRI.
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we relinquished to consider tumors that were grown for the
same period of time, but rather compared tumors of similar
sizes (at least 5 mm diameter) and lacking extended areas
of necrosis.
For quantitative analysis of DCE-MRI data, MR signal time
courses were determined from regions of interest defined
over the central part of the right ventricle (or the aorta) and
within each tumor. For each region, precontrast T1 relaxa-
tion times were estimated by nonlinear regression analysis
and used to convert measured signal time courses into
concentration–time courses [19].
Individual concentration– time courses were analyzed
using a pharmacokinetic two-compartment model [19], which
described the transport of Gd-chelate through capillaries
and its bidirectional transport between plasma and inter-
stitial space. Using the program MKMODEL (version 5.0;
Biosoft, Cambridge, UK), the permeability–surface area
product per unit of vascular volume (PS/VP), the RBV per
unit tissue mass RBV (ml/100 g tissue), and the RBF per unit
tissue mass RBF (ml/min/100 g tissue) were estimated
[19,35]. For each group, means and standard deviations
were calculated. Additionally, aggregated concentration–
time courses of tumors were generated by averaging the
individual concentration–time courses determined for six
different groups (three sublines and two localizations).
In vivo [1H]MRS data were postprocessed and displayed
using the user interface jMRUI [36].
Histologic Evaluation
The rats were sacrificed when the tumor diameter ex-
ceeded 15 mm in subcutaneously implanted tumors and
10 mm in orthotopically implanted tumors.
For histologic phenotyping, tumors were dissected, cov-
ered with Tissue-Tek (Sakura, Zoeterwoude, The Nether-
lands), and frozen in liquid nitrogen vapor. Tumor sections
with a thickness of 6 mmwere cut using a Reichert-Jung Frigo-
cut 2700 microtome (Leica, Bensheim, Germany). For his-
tology, sectionswere stainedwith hematoxylin and eosin (HE).
Double-immunofluorescence images of endothelial cells
and pericytes were generated using primary antibodies
against PECAM-1 (mouse anti-rat anti-CD31 mAb, 1:50 con-
centration; Chemicon International, Temecula, CA) and rabbit
anti-rat Ng-2 (rabbit anti-rat Ng-2 pAb; Chemicon Inter-
national; 1:100 concentration), secondary TRSC-labeled
antibodies against mouse IgG (1:100 concentration; Dia-
nova, Hamburg, Germany), and Cy2-labeled antibodies
against rabbit IgG (1:50 concentration; Dianova). Alterna-
tively, staining of PECAM-1was combinedwith that of smooth
muscle actin (SMA). For this purpose, primary antibodies
against SMA (rabbit anti-human anti–SMA pAb, 1:100 con-
centration; Biozol, Eching, Germany) and secondary Cy2-
labeled antibodies against rabbit IgG (1:50 concentration;
Dianova) were used.
Apoptotic cells were assessed by terminal deoxyribosyl
transferase–mediated dUTP nick end labeling (TUNEL)
staining (In Situ Cell Death Detection Kit, TMR red; Roche
Diagnostics, Mannheim, Germany) performed according to
the instructions of the manufacturer.
In all cases, additional counterstaining was performed
using Hoechst nuclear staining (1:100 concentration; Invitro-
gen, Paisley, UK).
Tissue sections were viewed by phase-contrast micros-
copy, and images were captured with a digital camera (Color
View 1; Soft Imaging System GmbH, Muenster, Germany).
For fluorescence microscopy, a Leica microscope (DMRE,
Bensheim, Germany) with an adapted digital camera (F-view
XS; Soft Imaging System GmbH) was used. Quantitative
analysis of marker density on histologic sections was per-
formed by calculating positive area fractions using the Anal-
ysis Software (Soft Imaging System GmbH). In this context,
at least three different tumors per model and implantation
site were analyzed.
For each tumor, more than three different regions of in-
terests were placed randomly. Because the tumors did not
show marked central degradation, it was not necessary to
analyze tumor margins and centers separately.
Statistical Analysis
Differences in parameters characterizing tumor size, vas-
cularization, and immunohistology between groups were com-
pared using Student’s t test at a significant level of P = .05.
Results
Growth and Spread of PCa
In T2w MR images, subcutaneous tumors were clearly
identified as hyperintense relative to surrounding muscles,
whereas orthotopic tumors appeared hypointense relative to
normal prostate tissues. In both cases, a clear delineation of
PCa from surrounding tissues and, thus, reliable determina-
tion of tumor diameters were feasible.
Subcutaneous tumor induction was successful in all H
tumors (n = 12), HI tumors (n = 5), and AT1 tumors (n = 7).
Orthotopic implantation of H sublines, however, succeeded
in only 7 of 12 cases, but in all HI tumors (n = 6) and AT1
tumors (n = 6).
As expected from the characteristics of the tumor sub-
types [31], the growth of tumors diverged and increased from
H tumors, to HI tumors, to AT1 subtypes for both implanta-
tion sites. The comparison of orthotopic tumor growth and
subcutaneous tumor growth indicated that H tumors grew
significantly (P < .05) slower in the prostate than in sub-
cutaneous localization (Figure 2). In contrast, the growth of
orthotopic versus subcutaneous HI and AT1 tumors did not
differ significantly, respectively. Surprisingly, in the case of
orthotopic versus subcutaneous HI tumors, lymph node
metastases were observed in four of six animals, whereas
no metastasis was found for the other models.
Histologic Phenotypes
HE-stained histologic sections of H, HI, and AT1 tu-
mors exhibited marked phenotypical differences (Figure 3).
H tumors showed high stromal density and tubular struc-
tures similar to those found in normal prostate tissues. On
the contrary, HI tumors tended to form irregular ring-like
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structures filled with large amounts of mucin, whereas AT1
tumors were found to be anaplastic without tubular struc-
tures. Thus, glandular differentiation was associated with
slow tumor growth. In this context, immunohistologic analy-
sis indicated that glandular differentiation was associated
with a close interaction of tumor cells and smooth muscle
cells (SMC). Accordingly, SMC fractions decreased from H
tumors, to HI tumors, to AT1 tumors (Figures 4 and 5). SMC
associated with mature vessels represented only a minor
fraction in H tumors, but were dominant in HI and AT1 tumors.
Between orthotopic and subcutaneous HI and AT1
tumors, there was no obvious difference in histomorphology
(Figures 4 and 5). In contrast, subcutaneously growing
H tumors frequently showed dedifferentiated areas with
polyploid tumor cells that were not visible in orthotopic lo-
cations. In addition, comparedwith subcutaneous ones, there
was a significant decrease in the area fraction of SMC in
orthotopic H tumors. Morphologically, this was reflected by
Figure 2. Acceleration of tumor growth. Growth of H, HI, and AT1 tumors
after orthotopic placement (closed line) and subcutaneous placement (dotted
line). Differentiated H tumors showed the slowest growth rates, whereas
anaplastic AT1 tumors displayed the fastest growth rates. Comparing tumor
growth after orthotopic and subcutaneous implantations, orthotopic H tumors
showed retarded growth (P < .05, starting on day 11), whereas orthotopic HI
tumors exhibited accelerated growth. Differences in the growth rates of
orthotopic and subcutaneous AT1 tumors were not significant. Note: The
decline of the growth curve of orthotopic AT1 tumors on day 17 resulted from
the removal of three animals with symptomatic disease.
Figure 3. HE staining of Dunning PCa. Images of HE-stained orthotopic tumors (A, C, E) and subcutaneous (B, D, F) H tumors (A and B), HI tumors (C and D), and
AT1 tumors (E and F). The corresponding T2w MR images are supplemented on the upper left part of each image. Tumors are labeled with arrows. The loss of
differentiation from H tumors, to HI tumors, to AT1 tumors is visible. Orthotopic H tumors are highly differentiated and show tubular structures. (A) Dedifferentiated
areas, however, are frequently found in subcutaneous H tumors. (B) HI tumors (C and D) secrete mucin, which is found in large lacunes mimicking tubular
structures. AT1 tumors (E and F) have an anaplastic phenotype without distinct resemblance to the tissue of origin. Both HI tumors (C and D) and AT1 tumors (E
and F) do not show marked differences for the two implantation sites. Bar = 100 m.
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the frequently incomplete or absent surroundings of tubular
tumor cell islets by SMC.
All tumor models showed a highly heterogeneous pattern
of TUNEL staining (apoptosis) without significant differences
between sublines and between orthotopic and subcutaneous
tumors (Figures 4 and 5).
Vessel density, as determined by CD31 immunostaining,
diverged between the different tumor models and implan-
tation sites (Figures 4 and 5). A significantly higher vessel
density was observed in orthotopic H tumors compared
with subcutaneous ones (P < .05) and with subcutaneous
AT1 tumors (P < .01). Cross correlation between the other
conditions did not indicate significant differences. The area
fractions of mature vessels, as indicated by Ng-2 immuno-
staining, decreased from H tumors to HI tumors to AT1
tumors. Significant differences were found for H and AT1
tumors in both implantation sites. However, the comparison
of orthotopic and subcutaneous tumors did not indicate sig-
nificant differences (Figures 4 and 5).
Assessment of Vessel Function by DCE-MRI
H, HI, and AT1 tumors could not be distinguished based
on their RBVand permeability–surface area product (PS/Vp).
In comparing orthotopic versus subcutaneous tumors, there
were no significant differences according to these physiolog-
ical parameters. RBF, however, was lower in orthotopic H
tumors, such as in subcutaneous ones, and in HI tumors
(P < .05) and AT1 tumors at both implantation sites. Further-
more, as a general tendency, cumulated concentration–time
curves showed higher values for subcutaneous tumors of all
sublines (Table 1, Figure 6).
Assessment of Tumor Metabolism by [1H]MRS
Localized in vivo [1H]MR spectra of subcutaneous tumors
showed good reproducibility on comparison between the
three repeated measurements (performed with the same
experimental parameters and voxel positions) of the same
tumor. In addition, for different subcutaneous tumors of the
same subline, comparable spectra were obtained.
However, the spectral pattern of H, HI, and AT1 sublines
examined in this study differed distinctly. As expected for
anaplastic tumors with rapid membrane turnover [16], there
was a distinct Cho peak (d = 3.2 ppm) in AT1 tumors. The
interpretation of resonances at 3.2 ppm in the H and
HI spectra (Figure 7), however, was more complex because
of the presence of a pair of lines resonating at 3.2 and
Figure 4. Results from immunostaining. Plots of mean positive area fractions of SMA, TUNEL, CD31, and Ng-2 (± standard deviation) in orthotopic and
subcutaneous PCa of H, HI, and AT1 sublines. SMA area fractions decreased from H tumors to AT1 tumors and have significantly higher values in orthotopic H
tumors compared with all other tumors and subcutaneous H tumors with subcutaneous HI tumors and both AT1 tumors. Differences between orthotopic HI tumors
and both AT1 tumors, as well as subcutaneous HI tumors and orthotopic AT1 tumors, were also significant. According to TUNEL staining, no significant differences
were observed between the three tumor sublines in orthotopic and subcutaneous locations. Vessel density (CD31) was significantly higher in orthotopic H tumors
as in subcutaneous H and AT1 tumors. Ng-2 decreased from H tumors, to HI tumors, to AT1 tumors without showing significant differences between the orthotopic
and subcutaneous implantation sites of the same subline, but with significant decrease between both H tumors and both AT1 tumors. *P < .05.
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3.4 ppm, with the first one overlapping with the choline
peak. According to measurements in model solutions at 7 T
[37], these resonances (indeed two unresolved triplets) were
attributed to taurine (Tau). Although the Cho intensity domi-
nated in the AT1 tumor spectrum at 3.2 ppm, the cor-
responding signals in H and HI tumors originated mainly
from Tau, as it is known to interact with SMC [38] and to
reduce lipolysis [39].
Further inspection of Figure 7 showed that the signal
intensity of unsaturated lipid fraction (free fatty acids and
triacylglycerides; chemical shift range d = 0.8–1.5 ppm)
increased from differentiated H tumors to HI tumors to ana-
plastic AT1 tumors.
In summary, the results indicate that for differentiated
H tumors, implantation site highly influences growth, whereas
it is less relevant for highly dedifferentiated HI and AT1
tumors. Two major phenotypical differences were observed
between orthotopic and subcutaneous H tumors. Firstly, the
density of CD31-positive vessels was significantly increased
in orthotopic H tumors. Secondly, the SMC density asso-
ciated with tubular tumor cell islets was reduced in sub-
cutaneous H tumors and in the more dedifferentiated HI
and AT1 tumors. In this context, it might be interesting to
Figure 5. Triple-immunofluorescence images of CD31, Ng-2, and DAPI of H, HI, and AT1 tumor sections. Ng-2 (green) colocalized with CD31-positive (red)
vessels but could not be found on the surface of tumor cells. Furthermore, comparing H tumors (A and B) with HI tumors (C and D) and AT1 tumors (E and F) at
both location sites, a significant decrease in the amount of Ng-2–positive vessels was observed. No significant difference was found on comparing subcutaneous
and orthotopic tumors. The triple-immunofluorescence images of CD31 (red), SMA (green), and DAPI (blue) of H, HI, and AT1 tumor sections are shown in (G) to
(L). In orthotopic H tumors, most SMAs localized around glandular tumor islets, and only minor amounts were associated with CD31-positive vessels. In
subcutaneous H tumors, the association of SMC and tumor cells decreased, and the surroundings of tubular tumor cell specifications were frequently incomplete or
absent (arrows). In HI and AT1 tumors, SMA was predominantly found along vascular structures, which is true for both implantation sites. Almost no direct
association of glandular tumor cell islets and SMC could be observed. Bar = 100 m.
Table 1. Parameters of Tumor Vascularization (Mean ± Standard Deviation)







H orthotopic 1.6 ± 3.9 3.1 ± 2.8 63 ± 36
H subcutaneous 1.6 ± 1.3 2.2 ± 0.5 108 ± 35
HI orthotopic 1.8 ± 2.8 1.9 ± 0.6 109 ± 22
HI subcutaneous 1.0 ± 2.7 1.9 ± 0.5 145 ± 53
AT1 orthotopic 1.0 ± 3.5 3.1 ± 2.3 119 ± 110
AT1 subcutaneous 1.2 ± 2.8 2.2 ± 0.5 127 ± 79
Figure 6. Concentration– time courses from DCE-MRI. The concentration–
time courses were averaged over tumors within each of the six groups.
Higher concentrations of the contrast agent compared to their orthotopic
counterparts are accumulated in subcutaneous tumors.
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know that [1H]MRS indicated that H, HI, and AT1 tumors
contained different amounts of Tau, which is known to play a
role in the stabilization and differentiation of SMC. The pos-
sible association of these findings will be discussed in detail
in the Discussion section.
Discussion
Our results from noninvasive imaging, in combination with
histologic evaluation of experimental PCa, demonstrate sev-
eral novel findings on the influence of microenvironment
on the PCa phenotype: 1) the growth of highly differentiated
H tumors was influenced by implantation site; 2) influence
seemed less important for the development of intermediate
malignant HI tumors and anaplastic AT1 tumors; 3) in ortho-
topic H tumors, SMC had a close interaction with glandular
tumor islets, which was reduced in subcutaneous H tumors
and was almost absent in HI and AT1 tumors; 4) microcircu-
latory parameters estimated from DCE-MRI data did not
show significant differences between tumor types, whereas
higher perfusion values were observed in all subcutaneous
tumors compared to orthotopic ones; 5) microvessel density
was increased in orthotopic H tumors compared with sub-
cutaneous ones and other models at both implantation sites;
6) the amount of mature vessels decreased from H tumors,
to HI tumors, to AT1 tumors; and 7) [1H]MRS indicated a
decrease in Tau and an increase in lipid components from low
to high malignant tumors.
These observations may point to an important mecha-
nism of PCa dedifferentiation and to the need of tumor
models grown in an adequate microenvironment. From
various tumors [40], such as bladder carcinomas [41], colon
carcinomas [42], renal carcinomas [43], and PCa [44], it is
already known that the tumor phenotype and its metastatic
potential are different between orthotopic and subcuta-
neous tumors. In addition, using the Dunning AT3 PCa
model, different routes of systemic spread were described
for orthotopically and subcutaneously grown tumors [45].
Subcutaneous tumors grown in the flank exhibited lung
metastases, whereas those grown in the prostate metasta-
sized locally. They also displayed a higher take rate when
implanted orthotopically. In contrast, in our study, highly
differentiated H tumors had a lower take rate and slower
growth when implanted orthotopically, whereas HI and AT1
tumors grew in both locations comparably (Figure 1). How-
ever, in HI tumors, we detected macroscopic lymph node
metastases only after orthotopic implantation, which is in line
with the findings of Glinskii et al. [44] describing the presence
of circulating tumor cells of PC-3 PCa in nude mice only after
orthotopic implantation.
Significant differences in growth were observed between
subcutaneous and orthotopic H tumors. The H tumor subline
represents an experimental tumor quite similar to that found
in humans, and there are several studies dealing with hor-
mone dependence and growth pattern. Although Lubaroff
and Culp [46] reported glandular differentiation both for
orthotopic and subcutaneous tumors, we regularly found de-
differentiated islets only in H tumors grown subcutaneously.
Figure 7. [1H]MRS of subcutaneous Dunning PCa. Localized in vivo [1H]MR
spectra of subcutaneous H, HI, and anaplastic AT1 tumors [PRESS technique:
water signal suppression, TR = 2000 milliseconds, TE = 14 milliseconds,
number of excitations = 128, voxel size = 4  4  4 mm3, planar surface coil
B0 = 9.4 T]. The chemical shift scale (d) could be fixed by identification of the
peaks of >N-CH3 protons of Cr (H and AT1) and of methylene and methyl
protons of lipids (Lip) (HI and AT1). Analysis of the multiline spectrum of AT1
tumors yielded the signal of methylene protons of Cr at d = 3.9 ppm, whereas
the resonance at d = 3.2 ppm appeared as a superposition of the N-trimethyl
proton signal of Cho and a signal at about 3.25 ppm (shoulder at the low-field
side). This signal, together with the peaks at d = 3.52 and 4.1, was tentatively
assigned to myo-inositol (mIns) using chemical shifts (d = 3.28, 3.52, 3.62, and
4.06 ppm) measured at B0 = 7.0 T for mIns model solution [37]. Inspection of
the spectrum of H tumors led to the assignment of two peaks of equal intensity
at about 3.2 ppm (with possible signal contribution of Cho) and 3.4 ppm
(measured chemical shift difference: 0.17 ppm) to Tau when referring to shifts
d = 3.26 ppm (triplet) and 3.43 ppm (triplet) observed in a Tau model solution
at B0 = 7.0 T [37]. Tau was observed in all three spectra. The peaks at d = 2.05
(resolved in all spectra) and 3.75 ppm (HI and AT1) with varying intensities
could not be assigned unambiguously.
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These may be derived from new tumor cell mutations occur-
ring during the growth of tumors or from the preexisting 8%
to 30% HI cells, which have been described by Smolev et al.
[47] to initiate growth soon after castration.
Under normal conditions, androgen-dependent stromal
cells play a crucial role in maintaining a fully differentiated
growth-quiescent gland. It is also known that prostatic
carcinogenesis is associated with changes in interactions be-
tween the stromal microenvironment and tumor cells [7,48].
In this context, Cunha et al. [7] found progressive loss of
SMC and appearance of carcinoma-associated fibroblasts.
Thus, slow growth and high differentiation of orthotopic H
tumorsmight have been preserved by a close interaction with
stromal cells. The growth of hormone-independent HI and
anaplastic AT1 tumors, however, may depend, to a lesser
extent, on implantation site due to minor requirements for
stromal interaction and better adaptation to varying implan-
tation sites caused by clonal mutation and selection [7]. Here,
malignant stroma may contribute more for maintaining the
three-dimensional tumor architecture [49] than for keeping
a differentiated tumor phenotype.
Tumor growth and differentiation strongly depend on blood
supply, vascularization, and angiogenesis [50–52]. Ac-
cordingly, in our models, significant differences in tumor
vascularization were observed. A decrease in mature ves-
sel fractions from H tumors, to HI tumors, to AT1 tumors was
observed, which is in line with previous observations describ-
ing a negative correlation of tumor malignancy with vessel
maturity for different tumor entities [53]. However, orthotopic
H tumors developed the highest vessel density of all models
and presented a higher density of Ng-2–positive mature
vessels than AT1 and HI tumors. The observation of a higher
vessel density in orthotopic Dunning PCa is in line with the
findings of Chen et al. [54], who found a higher total vessel
density in anaplastic MatLyLu-Dunning carcinomas grown in
the prostate compared with subcutaneous tumors. However,
it remains uncertain why, in our study, this was only true for
differentiated H tumors, whereas for highly dedifferentiated
HI and AT1 tumor models, we did not observe significant
differences in vessel density between orthotopic and subcu-
taneous tumors. Besides the influence of the local micro-
environment on tumor angiogenesis, the high vessel density
(CD31) and the high fraction of Ng-2–positivemature vessels
observed in low malignant orthotopic H tumors may also be
explained by slow tumor growth, giving tumors more time to
develop a stable and functional vascularization [55,56].
Surprisingly, orthotopic H tumors showed perfusion lower
than those of subcutaneous ones and HI and AT1 tumors,
independent of their implantation site. An explanation as to
why higher vessel density may not go along with increased
RBV and perfusion is that a relevant amount of tumor blood
vessels, which are evaluated histologically, may not function-
ally contribute to tumor blood supply [57]. Mature vasculari-
zation with a lower frequency of vascular shunts may be
another explanation for the reduced perfusion in orthotopic
H tumors. Furthermore, histologic evaluation does not con-
sider the quality of feeding and draining host vessels and the
level of interstitial pressure [52,58]. Thus, recruitment of host
blood and lymphatic vessels from different host tissues
may be variable, and its resulting consequences on inter-
stitial pressure may also explain changed tumor perfusion.
This hypothesis is strengthened by the fact that all sublines
exhibited lower perfusion in orthotopic implantation sites.
A high number of metabolites of low molecular mass were
detected in tumors in vivo using high-resolution [1H]MRS at
9.4 T. Firstly, the concentration of free fatty acids increased
from highly differentiated H tumors to less differentiated HI
to AT1 tumors. This is in agreement with findings in hepato-
cellular carcinogenesis [22] and may result from increasing
amounts of free lipids, owing to aggravated lipolysis in
tumors, enhanced membrane turnover, and the development
of micronecrosis. Secondly, a significant increase in the level
of Cho (mainly phosphocholine and glycerophosphorylcho-
line) as intermediates of membrane synthesis and degra-
dation was observed in anaplastic AT1 tumors, which is in
line with the clinical findings on PCa, brain tumors, and other
neoplasias [59]. In contrast, in H and HI tumors, major con-
tributions to the peak at d = 3.2 ppm were assigned to Tau,
and the amount rose in contrasting ranges of lipid com-
ponents from AT1 tumors, to HI tumors, to H tumors. Tau is
known to decrease lipid peroxidation and can reverse the
contractile dysfunction of SMC [39]. Moreover, Tau restores
the secretion and expression of extracellular superoxide
dismutase, a glycoprotein secreted from vascular SMC [38].
Darnowski et al. [60] found amechanismbywhich taurolidine,
a derivate of Tau, caused cell death by apoptosis; therefore,
Jacobi et al. [61] were successful in pointing out the anti-
cancerogenic and antiangiogenic effects of taurolidine. Apop-
tosis indicated by TUNEL staining, however, was not shown
to increase in our tumor models with high Tau levels.
Taking into account the data from the literature and our
findings, we postulate that the levels of Tau in PCa may have
an impact on tumor malignancy by modulating the interaction
of tumor and SMC, which seems to be a prerequisite for
differentiated phenotype. However, these findings have to be
validated on PCa specimens of patients to elucidate whether
the association of SMC with tumor cells and the levels of Tau
and lipids in PCa can be used as diagnostic indicators of
tumor malignancy.
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